W. Schleif

发表

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

J. Condra, W. Schleif, O. M. Blahy, 1995, Nature.

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

J. Mellors, J. Condra, W. Schleif, 1996, Journal of virology.

Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses.

E. Wimmer, W. Schleif, E. Emini, 1985, Virology.

The immune response to poliovirus-specific synthetic peptides: effects of adjuvants and test animal species.

E. Wimmer, W. Schleif, E. Emini, 1985, Journal of virological methods.

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.

P. Darke, W. Schleif, J. Quintero, 1992, Journal of Medicinal Chemistry.

Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.

W. Schleif, J. Quintero, J. Nunberg, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Henryk Mach, Norman L. Letvin, Michelle A. Lifton, 2002, Nature.

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Michael D. Miller, W. Schleif, R. Geleziunas, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.

Karen Holmes, Kathy Lyons, Joseph Kessler, 2004, Bioorganic & medicinal chemistry letters.

A combinatorial library of indinavir analogues and its in vitro and in vivo studies.

Yuan Cheng, Xin Xu, Lawrence C Kuo, 2002, Bioorganic & medicinal chemistry letters.

Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.

D. Richman, H. Günthard, S. Frost, 2001, The Journal of infectious diseases.

Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

E. Miranda, R. Varadarajan, W. Schleif, 2006, The Biochemical journal.

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

S. Matsushita, W. Schleif, E. Emini, 1990, Journal of virology.

A potent and orally active HIV-1 integrase inhibitor.

Wei Xu, D. Hazuda, Michael D. Miller, 2007, Bioorganic & medicinal chemistry letters.

Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells

W. Schleif, H. L. Robbins, E. Roth, 1992, Journal of virology.

Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.

H. M. Langford, D. Hazuda, W. Schleif, 2008, Bioorganic & medicinal chemistry letters.

L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro

W. Schleif, J. Quintero, E. Emini, 1992, Antimicrobial Agents and Chemotherapy.

High-Potency Human Immunodeficiency Virus Vaccination Leads to Delayed and Reduced CD8+ T-Cell Expansion but Improved Virus Control

A. Perelson, M. Davenport, R. Ribeiro, 2005, Journal of Virology.

Mamu-A*01 Allele-Mediated Attenuation of Disease Progression in Simian-Human Immunodeficiency Virus Infection

J. Shiver, W. Schleif, E. Emini, 2002, Journal of Virology.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site.

W. Schleif, E. Emini, D. Zink, 1990, Molecular pharmacology.

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.

D. Walters, P. Darke, W. Schleif, 1996, Journal of medicinal chemistry.

Nonpeptidal P2 Ligands for HIV Protease Inhibitors: Structure‐Based Design, Synthesis, and Biological Evaluation.

Arun K. Ghosh, D. Walters, P. Darke, 1996 .

Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.

D. Hazuda, W. Schleif, E. Emini, 2004, Bioorganic & Medicinal Chemistry Letters.

Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.

D. Hazuda, Ping Chen, W. Schleif, 2004, Bioorganic & medicinal chemistry letters.

Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade

W. Schleif, E. Emini, W. Long, 1986, Journal of virology.

Attempted prophylaxis of human immunodeficiency virus type 1 infection in chimpanzees with a nonnucleoside reverse transcriptase inhibitor.

W. Schleif, E. Roth, K. Murthy, 1994, AIDS research and human retroviruses.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.

D. Hazuda, W. Schleif, E. Emini, 2004, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.

D. Hazuda, Ping Chen, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Combinatorial synthesis of CCR5 antagonists.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp 41 epitope

D. Hazuda, R. Cortese, G. Ciliberto, 2005 .

Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine.

W. Schleif, E. Emini, M. Silberklang, 1988, Virology.

Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.

L. Kuo, W. Schleif, L. Gabryelski, 2002, Bioorganic & medicinal chemistry letters.

Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.

L. Kuo, W. Schleif, L. Gabryelski, 2000, Bioorganic & medicinal chemistry letters.

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Mark Embrey, Samson M Jolly, Wei Xu, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.

D. Hazuda, W. Schleif, E. Emini, 2005, Bioorganic & medicinal chemistry letters.

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

P. Darke, W. Schleif, O. M. Blahy, 1994, Proceedings of the National Academy of Sciences of the United States of America.

HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.

Jiunn H. Lin, L. Kuo, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.

Linghang Zhuang, D. Hazuda, W. Schleif, 2003, Journal of medicinal chemistry.

Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.

Yuan Cheng, Jiunn H. Lin, W. Schleif, 2002, Bioorganic & medicinal chemistry letters.

Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.

Jiunn H. Lin, L. Kuo, W. Schleif, 2002, Bioorganic & medicinal chemistry letters.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2004, Bioorganic & medicinal chemistry letters.

4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.

H. M. Langford, D. Hazuda, W. Schleif, 2000, Journal of medicinal chemistry.

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

D. Hazuda, Jiunn H. Lin, W. Schleif, 2005, Bioorganic & medicinal chemistry letters.

P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.

W. Schleif, E. Emini, K. Chapman, 2004, Bioorganic & medicinal chemistry letters.

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

J A Grobler, Amy S. Espeseth, D. Hazuda, 2000, Science.

HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.

Jiunn H. Lin, L. Kuo, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.

Jiunn H. Lin, L. Kuo, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.

Louis-David Cantin, Lawrence C Kuo, Ralph Hirschmann, 2003, Journal of medicinal chemistry.

Pyrrolinone-Based HIV Protease Inhibitors. Design, Synthesis, and Antiviral Activity: Evidence for Improved Transport

P. Darke, W. Schleif, E. Emini, 1995 .

Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

E A Emini, K., W. Schleif, 1991, Journal of virology.

3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Arun K. Ghosh, P. Anderson, P. Darke, 1993, Journal of the American Chemical Society.

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.

P. Darke, W. Schleif, T. Tucker, 1992, Journal of medicinal chemistry.

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Joseph Kessler, Anthony Carella, D. Hazuda, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors

P. Anderson, Jiunn H. Lin, P. Darke, 1994 .

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

P. Darke, W. Schleif, J. Quintero, 1994, Journal of medicinal chemistry.

5‐Chloro‐3‐(phenylsulfonyl)indole‐2‐carboxamide: A Novel, Non‐ Nucleoside Inhibitor of HIV‐1 Reverse Transcriptase.

W. Greenlee, P. Anderson, T. Ciccarone, 1994 .

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

D. Richman, D. Havlir, J. Mellors, 1998, JAMA.

Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption

B. E. Evans, P. Anderson, Jiunn H. Lin, 1995 .

Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.

L. Kuo, W. Schleif, S. Munshi, 2006, Bioorganic & medicinal chemistry letters.

Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.

Jiunn H. Lin, W. Schleif, L. Gabryelski, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 5R- and 5S-methyl substituted D- and L-configuration 1,3-dioxolane nucleoside analogs.

W. Schleif, J. Tomassini, M. Maccoss, 2004, Bioorganic & Medicinal Chemistry.

A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase

Michael S. Saag, George M. Shaw, J. Kappes, 1993 .

L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

W. M. Sanders, P. Darke, I. Sigal, 1991, Journal of medicinal chemistry.

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.

E A Emini, P. Anderson, P. Darke, 1991, Journal of medicinal chemistry.

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

W. Schleif, E. Emini, J. Nunberg, 1992, Nature.

HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.

W. M. Sanders, P. Anderson, P. Darke, 1993, Drug design and discovery.

Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

D. Hazuda, J. Shiver, W. Schleif, 2004, Science.

Active human immunodeficiency virus protease is required for viral infectivity.

L J Davis, E A Emini, R. Dixon, 1988, Proceedings of the National Academy of Sciences of the United States of America.

A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity.

W. Schleif, E. Emini, J. Lewis, 1988, Journal of virological methods.

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.

C. Petropoulos, J. Condra, W. Schleif, 2000, The Journal of infectious diseases.

Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

J. Condra, W. Schleif, A. Rhodes, 1993, Antimicrobial Agents and Chemotherapy.

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.

J. Kappes, M. Saag, W. Schleif, 1993, The New England journal of medicine.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.

D. Hazuda, W. Schleif, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.

E A Emini, L. Kuo, P. Darke, 2000, Journal of medicinal chemistry.

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.

E A Emini, Arun K. Ghosh, P. Darke, 1993, Journal of medicinal chemistry.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Gennaro Ciliberto, Peter S Kim, Simon Lennard, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag

D. Watkins, D. O’Connor, J. Shiver, 2005, Journal of Virology.

Cytotoxic T-Lymphocyte Escape Does Not Always Explain the Transient Control of Simian Immunodeficiency Virus SIVmac239 Viremia in Adenovirus-Boosted and DNA-Primed Mamu-A*01-Positive Rhesus Macaques

Kendall C. Krebs, D. Watkins, D. O’Connor, 2005, Journal of Virology.

Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys

J. Shiver, W. Schleif, L. Gabryelski, 2005, Journal of Virology.

2-Heterocyclic indole-3-sulfones as inhibitors of HIV-1 reverse transcriptase

W. Schleif, J. Huff, J. O'brien, 1995 .

Efficacy of Multivalent Adenovirus-Based Vaccine against Simian Immunodeficiency Virus Challenge

D. Watkins, D. O’Connor, J. Shiver, 2009, Journal of Virology.

Efficacy of indinavir–ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures

Jennifer L. Wright, J. Condra, W. Schleif, 2003, AIDS.

The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.

B. Connolly, J. Shiver, W. Schleif, 2004, Virology.

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2003, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors

J. Condra, W. Schleif, E. Emini, 1993, Antimicrobial Agents and Chemotherapy.

Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products.

D. Hazuda, W. Schleif, P. Felock, 2003, Journal of natural products.

The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate

H. Katinger, W. Schleif, E. Emini, 1996, Journal of virology.

The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection.

Leslie L. Chavez, A. Perelson, M. Davenport, 2008, Virology.

Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection.

J. Shiver, W. Schleif, E. Emini, 2007, Virology.

Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles

P. Anderson, P. Darke, W. Schleif, 1995 .

Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors

P. Anderson, P. Darke, W. Schleif, 1995 .

A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability

P. Anderson, P. Darke, W. Schleif, 1994 .

Structure-activity studies and antiviral properties of hydroxyethylene transition state inhibitors of HIV-1 protease

P. Anderson, P. Darke, W. Schleif, 1992 .

A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2006, Bioorganic & medicinal chemistry letters.

Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design

Raghavan Varadarajan, Kausik Chakraborty, Prem Sinha, 2005, Journal of Virology.

Vero cell‐expressed Epstein‐Barr virus (EBV) gp350/220 protects marmosets from EBV challenge

W. Schleif, E. Emini, R. Ellis, 1989, Journal of medical virology.

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.

D. Hazuda, W. Schleif, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.

W. Schleif, L. Gabryelski, E. Emini, 2003, Bioorganic & medicinal chemistry letters.

Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees.

W. Schleif, J. Quintero, E. Emini, 1990, AIDS research and human retroviruses.

Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors

E A Emini, J. Condra, W. Schleif, 1994, Antimicrobial Agents and Chemotherapy.

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay.

G. Ciliberto, J. Shiver, W. Schleif, 2004, Journal of immunological methods.

Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.

W. Schleif, L. Gabryelski, E. Emini, 2007, Bioorganic & medicinal chemistry letters.

In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds.

J. Condra, W. Schleif, P. Deutsch, 1996, Advances in experimental medicine and biology.

8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2007, Bioorganic & medicinal chemistry letters.

Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2007, Bioorganic & medicinal chemistry letters.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

Synthesis of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4- dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

W. M. Sanders, P. Anderson, W. Schleif, 1994 .

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.

J. Condra, W. Schleif, E. Emini, 1994, Archives of virology. Supplementum.

Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P2‐Ligands and Pyrazine. Amides as P3‐Ligands.

Arun K. Ghosh, P. Anderson, P. Darke, 1993 .

Efficacy of Multivalent Adenovirus-Based Vaccine against Simian Immunodeficiency Virus Challenge

D. Watkins, D. O’Connor, J. Shiver, 2009, Journal of Virology.

A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses

W. Schleif, K. Hsu, K. Lonberg-Holm, 1988, Journal of virology.

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.

S. Staszewski, W. Schleif, E. Emini, 1995, The Journal of infectious diseases.